The medical technology company Pexa reduced its revenue in the second quarter but at the same time halved its loss and signed its largest commercial agreement to date during the period. Net sales amounted to SEK 0.1 million (0.3).Net profit was SEK -1.2 million (-2.3). Earnings per share amounted to SEK -0.01 (-0.04).During the quarter, Pexa signed an agreement with one of the world's ten largest pharmaceutical companies for the delivery, installation and rental of ten Pexa systems for an international clinical study in pulmonary fibrosis. The agreement runs for 18 months and has an order value of approximately SEK 7.5 million.CEO Tomas Gustafsson states that the low reported revenue during the quarter does not fully reflect the commercial development. Pexa has invoiced EUR 325,000 under the pharmaceutical agreement, but the revenue will be recognized gradually over the contract period."Elsewhere, too, we are seeing usage grow. Norway's STAMI has purchased a PExA system for occupational health research during the year, and Germany's BAuA has expanded its usage through a second instrument. A US government agency customer has also ordered an upgrade of its existing system. For us, recurring and expanded business with established government and research customers provides important references as we continue to build the market," he writes in the report.After the end of the period, the company secured a total of just over SEK 26 million before issue costs through a rights issue, an over-allotment and a directed issue. According to the CEO, the capital provides the company with substantially greater financial room for maneuver for larger customer projects and continued development.At the beginning of September, Pexa will attend the ERS Congress in Barcelona, the world's largest meeting place for pulmonary medicine and respiratory research. "We are going there with a stronger scientific foundation, our largest commercial deal to date behind us and completely different financial conditions than just a few months ago," Gustafsson states. The company does not provide a financial earnings forecast.Key figures, SEK millionQ2 2026Q2 2025Year-over-year changeNet sales0.10.3-73.5%Net profit-1.2-2.3-Earnings per share, SEK-0.01-0.04-